Sutura Therapeutics Appoints James Noble and Eduardo Bravo to Board of Directors

Written by: Pharmiweb editor
Published on: 4 Mar 2020

​​Sutura Therapeutics Limited, a U.K.-based pharmaceutical company focused on discovering and developing novel gene medicines, today announces the appointments of James Noble and Eduardo Bravo to the Board of Directors.

James Noble will take the position of Chairman of the Board. He has held numerous senior executive positions, bringing over 35 years of experience in the international biotechnology industry and investment banking. James has previously served as Finance Director for British Biotechnology Group, raising over $300 million and taking the company public in London and on NASDAQ. Subsequently, he has been a founder and CEO of Avidex Limited, raising $60 million; he also co-founded Immunocore Limited, raising in excess of $400 million, and Adaptimmune Therapeutics PLC, raising over $650 million via partnering, private placings, a NASDAQ listing and subsequent secondary offerings. James is also a non-executive board member at Adaptimmune Therapeutics and Deputy Chairman of GW Pharmaceuticals (both NASDAQ-listed) and on the board of private company Celleron Therapeutics; he has previously held non-executive directorships at more than dozen biotechnology companies.

Eduardo has over 25 years’ experience in the biopharmaceutical industry and a strong track record in leading and growing international biotech and pharmaceutical organizations. From 2011-2018, he was CEO of TiGenix, a dual-listed (Euronext and NASDAQ) biopharmaceutical company developing novel stem cell therapies. Eduardo successfully developed TiGenix through several financing rounds, led its IPO on NASDAQ and secured European marketing approval of its lead asset. Prior to joining TiGenix's predecessor, Cellerix, in 2005, Eduardo held several senior management positions at Sanofi-Aventis and SmithKline Beecham. He was CEO of Nordic Nanovector, a public Norwegian company from July 2018 to February 2020, successfully completing two oversubscribed financing rounds with European and U.S. investors. He is currently Chairman of Vivet Therapeutics, a private gene therapy company. Eduardo holds a degree in Business Administration and an MBA from INSEAD.

"Sutura is honoured to welcome James and Eduardo to the Board at this exciting time in our evolution. With James as our first Chairman and Eduardo as Non-Executive Director, our ability to navigate the next steps into the clinic to address rare diseases has been substantially enhanced," commented Mark Beards, Director of Sutura. 

"I am very pleased to Chair the Board of Sutura and help bring breakthrough innovations to patients most in need," commented James Noble. "With its proprietary gene therapy technology that enables delivery of gene medicines to any affected tissue, I believe Sutura has the potential to revolutionise disease intervention and patient care."

Eduardo Bravo commented, "This is a fantastic opportunity to join a company with a true platform technology, and their patient-focused philosophy will greatly impact on human health."

Dr. Keith Foster, Founder and Chief Scientific Officer of Sutura stated, "With James, Eduardo and Mark at the helm, I anticipate that Sutura will be able to truly help those most in need, something at the core of our corporate philosophy."